Molecular Formula: C25H27N5O4S (alternatively, C24H23N5O·CH4SO3, depending on the salt form or representation method)
Molecular Weight: 493.58
Chemical Name: N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridinemethyl)amino-3-pyridinecarboxamide methanesulfonate
II. Physical Properties
Appearance: Film-coated tablets; after removing the coating, it appears white or almost white.
Density: Approximately 1.3±0.1 g/cm3
Boiling Point: 578.2±50.0 °C at 760 mmHg
Flash Point: 303.5±30.1 °C
Refractive Index: 1.652
Storage Conditions: Room temperature, dry, and sealed
III. Pharmaceutical Characteristics
Drug Target: Tyrosine kinase vascular endothelial growth factor receptor VEGFR-2
Mechanism of Action: By competitively inhibiting the binding site of ATP within VEGFR-2 cells, phosphorylation is blocked, downstream signal transduction is inhibited, and tumor angiogenesis is suppressed, thereby inhibiting tumor growth.
Indications: Currently, Apatinib Mesylate has been approved for multiple indications, including monotherapy for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after at least one prior line of systemic therapy has failed or is intolerable, advanced hepatocellular carcinoma, and in combination with Camrelizumab for unresectable or metastatic hepatocellular carcinoma. Additionally, Apatinib Mesylate is being investigated in clinical trials for breast cancer, ovarian cancer, non-small cell lung cancer, and other solid tumors.
